| dc.description.abstract |
The development of antimicrobial resistance by pathogenic bacteria has fuelled the search for alternatives to conventional antibiotics. Endogenous antimicrobial peptides have the potential to be used as new antimicrobial substances because they have low minimum inhibitory concentration in vitro, have broad-spectrum activity, neutralise lipopolysaccharides, promote wound healing and have synergistic effects with conventional antibiotics. Farm animals, in particular the blood that is a by-product of the meat and poultry industries, are an abundant, and currently underutilised, source of such antimicrobial peptides. These antimicrobial peptides could be isolated and developed into high-value products such as biopreservatives, topical neutraceutical products and pharmaceuticals. There have been some clinical trials of antimicrobial peptides as pharmaceutical products, but up to now, the trials have shown disappointing results. Further research and development is still needed before such peptides can be commercialised and full advantage taken of this waste product of the meat and poultry industries. |
|